01—Abstract
Summary
Summary of the 8-K filed November 8, 2024. Cited figures are marked; the original filing is the authoritative source.
On November 5, 2024, Cencora, Inc. (NYSE: COR) entered into a definitive agreement to acquire Retina Consultants of America (RCA), a leading management services organization (MSO) of retina specialists, from private equity owner Webster Equity Partners.
The deal is valued at an enterprise value of approximately $4.6 billiona, subject to customary working capital and net-debt adjustments. After accounting for RCA's rollover equity from affiliated practices, physicians and management, a planned cash capitalization of RCA, and transaction fees and expenses, Cencora's expected cash outlay at closing is approximately $4.3 billion. Cencora expects to own about 85% of RCA at closing and may pay up to $500 million in additional contingent consideration across fiscal years 2027 and 2028 if predefined business objectives are met.
The transaction is expected to be approximately $0.35b accretive to adjusted diluted EPS in the first twelve months, net of estimated financing costs. Cencora plans to fund the deal with a combination of cash on hand and new debt, and has obtained $3.3 billion in bridge financing commitments. Management emphasized maintaining its investment-grade credit rating and prioritizing de-leveraging after closing.
Fiscal 2025 guidance does not yet include RCA, and will be updated after the transaction closes. Closing is subject to customary conditions, including required regulatory approvals. Strategically, the acquisition expands Cencora's presence in community providers and its specialty business, building on its recent investment in OneOncology.
RCA operates with nearly 300 retina specialists across 23 states, over 2 million annual patient visits, and a clinical research network of 40 trial sites with 400 dedicated research employees. For investors, the key considerations are the size of the cash outlay relative to Cencora's balance sheet, the leverage impact and rating implications, and whether the company can execute on integration and the contingent earn-out targets.
02—Key points
Key Highlights
- Cencora agreed to acquire Retina Consultants of America, a leading retina-focused MSO, from Webster Equity Partners for an enterprise value of about $4.6 billion in cash.
- Expected cash outlay at closing is about $4.3 billion after rollover equity, planned cash capitalization of RCA, and fees; Cencora will hold roughly 85% ownership of RCA.
- Up to $500 million in additional contingent consideration may be paid in fiscal 2027 and 2028 based on predefined business objectives.
- The deal is expected to be approximately $0.35 accretive to adjusted diluted EPS in the first twelve months, net of estimated financing costs.
- Funding will come from cash on hand and new debt; $3.3 billion in bridge financing commitments have been obtained.
- Management reiterated commitment to its investment-grade credit rating and prioritizing de-leveraging after closing; fiscal 2025 guidance excludes RCA.
- RCA brings nearly 300 retina specialists across 23 states, over 2 million annual visits, and a clinical research network of 40 trial sites, expanding Cencora's specialty and MSO footprint.
03—Questions
Frequently Asked Questions
How large is the deal and how much cash will Cencora actually pay?
The enterprise value is approximately $4.6 billion, subject to working capital and net-debt adjustments. After rollover equity from RCA's affiliated practices, physicians and management, planned cash capitalization, and transaction fees, the expected cash outlay at closing is about $4.3 billion. Up to $500 million of additional contingent consideration could be paid in fiscal 2027 and 2028.
Will the acquisition be accretive to earnings?
Cencora expects the acquisition to be approximately $0.35 accretive to adjusted diluted EPS in the first twelve months after closing, net of estimated financing costs. This is a non-GAAP measure, and fiscal 2025 guidance does not yet reflect RCA.
How will Cencora finance the transaction and what does it mean for its credit rating?
The deal will be funded with a mix of existing cash and new debt, and Cencora has secured $3.3 billion in bridge financing commitments. Management stated it intends to maintain its investment-grade rating and prioritize de-leveraging in the years after closing, though the filing's risk factors note the ability to maintain that rating is a forward-looking uncertainty.
What are the main risks and conditions to closing?
Closing is subject to customary conditions, including receipt of required regulatory approvals. Risks cited include failure to close on the expected timetable, failure to achieve expected synergies, difficulty retaining key physicians and employees, business disruption, and the impact of leverage on the investment-grade rating.
What strategic value does RCA bring to Cencora?
RCA is a leading retina-focused MSO with nearly 300 retina specialists across 23 states, handling over 2 million annual visits, and a research network with 40 clinical trial sites. The deal extends Cencora's community provider and specialty strategy, complementing its recent investment in OneOncology, and expands its manufacturer services in clinical research.
04—Continue